LAP TGF-Beta Subset of CD4+CD25+CD127- Treg Cells is Increased and Overexpresses LAP TGF-Beta in Lung Adenocarcinoma Patients

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Islas Vazquez, Lorenzo ^a,b   Prado Garcia, Heriberto ^a   Aguilar Cazares, Dolores ^a   Meneses Flores, Manuel ^a   Galicia Velasco, Miriam ^a   Romero Garcia, Susana ^a   Camacho Mendoza, Catalina ^a   Lopez Gonzalez, Jose Sullivan ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LATENCY ASSOCIATED PEPTIDE; IL10 PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA; LATENCY-ASSOCIATED PROPEPTIDE, TGF-BETA; PEPTIDE; PROTEIN PRECURSOR; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER PATIENT; CD127 T LYMPHOCYTE; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LUNG ADENOCARCINOMA; MALE; REGULATORY T LYMPHOCYTE; SMOKING; T LYMPHOCYTE SUBPOPULATION; TH17 CELL; ADENOCARCINOMA; BIOSYNTHESIS; BLOOD; CANCER STAGING; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFLAMMATION; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADENOCARCINOMA; ADULT; AGED; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNE TOLERANCE; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-17; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKIN-4; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PEPTIDES; PROTEIN PRECURSORS; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84947447683     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/430943     Document Type: Article

References (38)

1. J. Lee, V. Taneja, and R. Vassallo, "Cigarette smoking and inflammation: cellular and molecular mechanisms, " Journal of Dental Research, vol. 91, no. 2, pp. 142-149, 2012.
2. M. R. Spitz, W. K. Hong, C. I. Amos et al., "A risk model for prediction of lung cancer, " Journal of the National Cancer Institute, vol. 99, no. 9, pp. 715-726, 2007.
3. M. R. Stämpfli and G. P. Anderson, "How cigarette smoke skewsimmune responses to promote infection, lung disease and cancer, " Nature Reviews Immunology, vol. 9, no. 5, pp. 377-384, 2009.
4. M. T. Chow, A. Möller, and M. J. Smyth, "Inflammation and immune surveillance in cancer, " Seminars inCancer Biology, vol. 22, no. 1, pp. 23-32, 2012.
5. A. Mantovani, P. Allavena, A. Sica, and F. Balkwill, "Cancerrelated inflammation, " Nature, vol. 454, no. 7203, pp. 436-444, 2008.
6. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation, " Cell, vol. 144, no. 5, pp. 646-674, 2011.
7. T. Korn, E. Bettelli, M. Oukka, and V. K. Kuchroo, "IL-17 and Th17 cells, " Annual Review of Immunology, vol. 27, pp. 485-517, 2009.
8. D. Alizadeh, E. Katsanis, and N. Larmonier, "The multifaceted role of Th17 lymphocytes and their associated cytokines in cancer, " Clinical and Developmental Immunology, vol. 2013, Article ID 957878, 11 pages, 2013.
9. R. P. Singh, S. Hasan, S. Sharma et al., "Th17 cells in inflammation and autoimmunity, " Autoimmunity Reviews, vol. 13, no. 12, pp. 1174-1181, 2014.
10. E. Maniati, R. Soper, and T. Hagemann, "Up for mischief? IL-17/Th17 in the tumour microenvironment, " Oncogene, vol. 29, no. 42, pp. 5653-5662, 2010.
11. G. A. Rabinovich, D. Gabrilovich, and E. M. Sotomayor, "Immunosuppressive strategies that are mediated by tumor cells, " Annual Review of Immunology, vol. 25, pp. 267-296, 2007.
12. H. Nishikawa and S. Sakaguchi, "Regulatory T cells in tumor immunity, " International Journal of Cancer, vol. 127, no. 4, pp. 759-767, 2010.
13. R. A. Peterson, "Regulatory T-cells: diverse phenotypes integral to immune homeostasis and suppression, " Toxicologic Pathology, vol. 40, no. 2, pp. 186-204, 2012.
14. E. M. Shevach and A. M. Thornton, "tTregs, pTregs, and iTregs: similarities and differences, " Immunological Reviews, vol. 259, no. 1, pp. 88-102, 2014.
15. W. Liu, A. L. Putnam, Z. Xu-yu et al., "CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells, "The Journal of ExperimentalMedicine, vol. 203, no. 7, pp. 1701-1711, 2006.
16. A. Schmidt, N. Oberle, and P. H. Krammer, "Molecular mechanisms of treg-mediated T cell suppression, " Frontiers in Immunology, vol. 3, article 51, 2012.
17. K. Nakamura, A. Kitani, and W. Strober, "Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor, " The Journal of Experimental Medicine, vol. 194, no. 5, pp. 629-644, 2001.
18. E. Y. Woo, C. S. Chu, T. J. Goletz et al., "Regulatory CD4(+)CD25(+) T cells in tumors from patients with earlystage non-small cell lung cancer and late-stage ovarian cancer, " Cancer Research, vol. 61, no. 12, pp. 4766-4772, 2001.
19. A. M. Wolf, D. Wolf, M. Steurer, G. Gastl, E. Gunsilius, and B. Grubeck-Loebenstein, "Increase of regulatory T cells in the peripheral blood of cancer patients, " Clinical Cancer Research, vol. 9, no. 2, pp. 606-612, 2003.
20. J. Mahalingam, C. Lin, J. Chiang et al., "CD4+ T cells expressing latency-associated peptide and Foxp3 are an activated subgroup of regulatory T cells enriched in patients with colorectal cancer, " PLoS ONE, vol. 9, no. 9, Article ID e108554, 2014.
21. M. Scurr, K. Ladell, M. Besneux et al., "Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3? T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells, " Mucosal Immunology, vol. 7, no. 2, pp. 428-439, 2014.
22. Z.-J. Ye, Q. Zhou, J.-C. Zhang et al., "CD39+ regulatory T cells suppress generation and differentiation ofTh17 cells in human malignant pleural effusion via a LAP-dependent mechanism, " Respiratory Research, vol. 12, articel 77, 2011.
23. L. Zhao, J. Yang, H.-P. Wang, and R.-Y. Liu, "Imbalance in the Th17/Treg and cytokine environment in peripheral blood of patients with adenocarcinoma and squamous cell carcinoma, " Medical Oncology, vol. 30, no. 1, article 461, 2013.
24. S. Li, Y. Li, X. Qu, X. Liu, and J. Liang, "Detection and significance of TregFoxP3+ andTh17 cells in peripheral blood of non-small cell lung cancer patients, " Archives ofMedical Science, vol. 10, no. 2, pp. 232-239, 2014.
25. E. Brambilla, W. D. Travis, T. V. Colby, B. Corrin, and Y. Shimosato, "The newWorld Health Organization classification of lung tumours, " European Respiratory Journal, vol. 18, no. 6, pp. 1059-1068, 2001.
26. P. A. Darrah, D. T. Patel, P. M. De Luca et al., "Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major, " Nature Medicine, vol. 13, no. 7, pp. 843-850, 2007.
27. H. Wang, H. Ying, S. Wang et al., "Imbalance of peripheral bloodTh17 and Treg responses in patientswith chronic obstructive pulmonary disease, "The Clinical Respiratory Journal, 2014.
28. F. Meloni, M. Morosini, N. Solari et al., "Foxp3 expressingCD4+ CD25+ and CD8+CD28-T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma, " Human Immunology, vol. 67, no. 1-2, pp. 1-12, 2006.
29. Y. Shigematsu, T. Hanagiri, H. Shiota et al., "Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor-specific cytotoxic T lymphocytes, " Oncology Letters, vol. 4, no. 4, pp. 625-630, 2012.
30. R. Li, D. Rüttinger, R. Li, L.-S. Si, and Y.-L. Wang, "Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer, " Langenbeck's Archives of Surgery, vol. 388, no. 6, pp. 406-412, 2003.
31. G. E. Carpagnano, A. Spanevello, C. Curci et al., "IL-2, TNF-, and leptin: local versus systemic concentrations in NSCLC patients, " Oncology Research, vol. 16, no. 8, pp. 375-381, 2007.
32. G. Landskron, M. De La Fuente, P. Thuwajit, C. Thuwajit, and M. A. Hermoso, "Chronic inflammation and cytokines in the tumor microenvironment, " Journal of Immunology Research, vol. 2014, Article ID149185, 19 pages, 2014.
33. C. Liao, Z. Yu, W. Guo et al., "Prognostic value of circulating inflammatory factors in non-small cell lung cancer: a systematic review andmeta-analysis, " Cancer Biomarkers, vol. 14, no. 6, pp. 469-481, 2014.
34. Q. Chang, L. Daly, and J. Bromberg, "The IL-6 feed-forward loop: a driver of tumorigenesis, " Seminars in Immunology, vol. 26, no. 1, pp. 48-53, 2014.
35. N. Erfani, S. M. Mehrabadi, M. A. Ghayumi et al., "Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC), " Lung Cancer, vol. 77, no. 2, pp. 306-311, 2012.
36. H. Prado-Garcia, S. Romero-Garcia, U. Rumbo-Nava, and J. S. Lopez-Gonzalez, "Predominance of Th17 over regulatory Tcells in pleural effusions of patients with lung cancer implicates a proinflammatory profile, " Anticancer Research, vol. 35, no. 3, pp. 1529-1535, 2015.
37. Y. Yamada, H. Saito, and M. Ikeguchi, "Prevalence and clinical relevance of Th17 cells in patients with gastric cancer, " Journal of Surgical Research, vol. 178, no. 2, pp. 685-691, 2012.
38. Q. Li, Q. Li, J. Chen et al., "Prevalence of Th17 and Treg cells in gastric cancer patients and its correlation with clinical parameters, " Oncology Reports, vol. 30, no. 3, pp. 1215-1222, 2013.